11 research outputs found
Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able
to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are
needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic
intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics
were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal
cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced)
ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented
statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements
were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that
followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were
proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities,
but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the
intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new
response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up
of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies
Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages
Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able
to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are
needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic
intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics
were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal
cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced)
ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented
statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements
were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that
followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were
proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities,
but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the
intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new
response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up
of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies
Trial of Deferiprone in Parkinson's Disease
Background Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. Methods We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. Results A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. Conclusions In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks